Pancreatic Cell News Volume 5.08 | Mar 4 2014

    0
    39
    Pancreatic Cell News 5.08 March 4, 2014

    Pancreatic Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Pancreatic Cell News on Twitter

     
    TOP STORY
    Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High Fat Diet Condition
    Scientists generated gastric inhibitory polypeptide (GIP)-GFP knock-in mice with a truncated prepro-GIP gene. The phenotype was assessed in heterozygous and homozygous state in mice on control fat diet and high fat diet in vivo and in vitro. [Diabetes] Abstract
    Directed Differentiation of Pluripotent Stem Cells - A Cell Stem Cell Poster

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    DIABETES & PANCREATITIS

    Alarmin High-Mobility Group B1 (HMGB1) Is Regulated in Human Adipocytes in Insulin Resistance and Influences Insulin Secretion in ß-Cells
    Investigators aimed to characterize the effect of insulin resistance on HMGB1 in adipose tissue and to examine its potential role as a metabolic regulator in ß-pancreatic cells. [Int J Obes] Abstract

    Protein Tyrosine Phosphatase-1B Modulates Pancreatic ß-Cell Mass
    Researchers studied the role of protein tyrosine phosphatase 1B (PTP1B) in pancreatic ß-cells. Silencing of PTP1B expression in a pancreatic ß-cell line revealed the significance of this endoplasmic reticulum bound phosphatase in the regulation of cell proliferation and apoptosis. [PLoS One] Full Article

    Bone Morphogenetic Protein Signaling Protects against Cerulein-Induced Pancreatic Fibrosis
    In vitro, bone morphogenetic protein (BMP)2 inhibited TGF-ß-induced extracellular matrix protein fibronectin production in wild-type pancreatic stellate cells (PSCs); this effect was abolished in BMPR2+/- PSCs. [PLoS One] Full Article

    Apoptosis Induced by Islet Amyloid Polypeptide Soluble Oligomers Is Neutralized by Diabetes-Associated Specific Antibodies
    Scientists describe the isolation of Type 2 diabetes-associated islet amyloid polypeptide soluble cytotoxic oligomers; these oligomers induced apoptosis in cultured pancreatic cells, permeated model lipid vesicles and interacted with cell membranes following complete internalization. [Sci Rep] Full Article

    PANCREATIC CANCER

    Targeting the Prohibitin Scaffold-CRAF Kinase Interaction in RAS-ERK-Driven Pancreatic Ductal Adenocarcinoma
    Prohibitin (PHB) expression was analyzed in human pancreatic cancer cell lines, normal pancreas, and pancreatic ductal adenocarcinoma tissue. Furthermore, genetic ablation or pharmacological inhibition of PHB was performed to determine its role in growth, migration, and signaling of pancreatic cancer cells in vitro and in vivo. [Mol Cancer] Full Article

    Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer
    Researchers showed that in human pancreatic cancer cells, oncolytic parvovirus H-1 activated multiple interconnected death pathways but failed to induce calreticulin exposure or ATP release. [J Virol] Abstract

    Orai1 and STIM1 Mediate SOCE and Contribute to Apoptotic Resistance of Pancreatic Adenocarcinoma
    Researchers demonstrated that ORAI1 and STIM1 mediate store-operated calcium entry (SOCE) in pancreatic adenocarcinoma cell lines. [Biochim Biophys Acta] Abstract

    The Multifunctional Growth Factor Midkine Promotes Proliferation and Migration in Pancreatic Cancer
    Scientists investigated the molecular role of Midkine in pancreatic cancer. It was found that Midkine is elevated in pancreatic ductal adenocarcinoma and differentially expressed in other histological subtypes of pancreatic cancer, whereas normal pancreatic cells did not express Midkine. [Mol Cancer Res] Abstract

    Gemcitabine Resistance Is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1 in Pancreatic Cancer Cells
    Gemcitabine-resistant pancreatic cancer cells acquired epithelial-mesenchymal transition phenotype. Moreover, gemcitabine-resistant cells have increased migration and invasion activities. [Curr Cancer Drug Targets] Abstract

    Webinar: Affordable, Defined hPSC Culture? Watch the video now.

     
    REVIEWS
    Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes
    The authors summarize recent advances in the differentiation of pancreatic ß cells from pluripotent stem cells (PSCs), and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, they discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes. [Stem Cell Rev] Abstract

    Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.

     
    INDUSTRY NEWS
    US FDA Approves Bydureon® Pen (Exenatide Extended-Release for Injectable Suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
    AstraZeneca announced that the US Food and Drug Administration (FDA) has approved the BYDUREON® Pen 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [AstraZeneca] Press Release

    DSI and Nova Sign Supply Agreement to Manufacture Telemetry Implant for Diabetes Research
    Data Sciences International (DSI) announced that Nova Biomedical (Nova) and DSI have signed a supply agreement for the development and manufacture of a fully implanted telemetry device for the continuous measurement of blood glucose in animal research applications. [Data Sciences International] Press Release

    From our sponsor:
    Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.

     
    POLICY NEWS
    National Cancer Institute Releases Report Outlining Scientific Framework to Address Pancreatic Cancer: A Statement from The Pancreatic Cancer Action Network
    The Pancreatic Cancer Action Network commends the National Cancer Institute, under the leadership of Harold E. Varmus, M.D., for issuing a report that takes important steps needed to make significant advances for one of The United States’ deadliest cancers. The report is a result of the Recalcitrant Cancer Research Act which was signed into law in January 2013 following a five-year push from the Pancreatic Cancer Action Network and its nationwide grassroots network. [Pancreatic Cancer Action Network] Press Release

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW EMBO | EMBL Symposium: Translating Diabetes
    April 30 – May 3, 2014
    Heidelberg, Germany

    Visit our events page to see a complete list of events in the pancreatic cell community.

     
    JOB OPPORTUNITIES
    NEW Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

    NEW PhD Studentship – Molecular Drug Resistance (Institute of Cancer Research)

    NEW Postdoctoral Position РDiabetes (Universit̩ de Sherbrooke)

    NEW Postdoctoral Position – Diabetes Research (Tel Aviv University)

    NEW Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

    PhD Studentship – Pancreatic Ductal Adenocarcinoma (Institute of Cancer Research)

    Postdoctoral Position – Diabetes (Washington University School of Medicine)

    Postdoctoral Research Fellow/Associate – Diabetes, Metabolism and Molecular Endocrinology (University of Illinois)

    Postdoctoral Positions – Cancer and Diabetes (University of Pennsylvania)

    Postdoctoral Fellow – Stem Cell Biology (McEwen Centre for Regenerative Medicine/University Health Network)

    Postdoctoral Associate Specialist РHuman Pancreatic Stem Cell Research (The Nestl̩ Institute of Health Sciences)

    Postdoctoral Fellowship Position – Mechanisms of Action in Obesity and Diabetes Pathogenesis (NIH/NIDDK)

    Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

    Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

    Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

    Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

    Comments or Suggestions? Submit your feedback here.

    Learn more about Pancreatic Cell News: Archives | Events | Contact Us